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Purpose/Objectivel: Targeted intraoperative radiation 
therapy (IORT) as an alternative to whole breast irradiation 
has been described for patients with early-stage breast 
cancer. The randomized phase III TARGiT trial demonstrated 
similar recurrence rates to WBI and a lower overall toxicity 
profile on short-term follow-up. We report on our early Latin 
American surgical experience using the Intrabeam 
radiotherapy delivery system. 
Materials and Methods: Prospectively gathered estrogen 
receptor-positive, clinically node-negative patients with 
invasive breast cancer < 2.5 cm receiving using the Intrabeam 
system were reviewed. IORT-related effects and early 
postoperative outcome were assessed.  
Results: Seventy eight patients (median age 67 years) 
underwent lumpectomy, sentinel lymph node biopsy, and 
concurrent IORT from march 2013 to march 2014. Ninety-five 
percent of patients had invasive ductal histology with a 
median tumor size of 1.5 cm.  
Conclusions: While a variety of APBI techniques are currently 
available for clinical use, our early Latin American operative 
experience with IORT shows it is well tolerated with low 
morbidity. The addition of WBI may be necessary in situations 
for positive residual margins or microscopic nodal disease in 
patients who do not undergo additional surgery. 
Implementation of IB impacts treatment planning and 
operating room use in a multidisciplinary breast cancer 
program. The safety profile, ease of administration, and 
reduced costs of IB favor its more widespread use in selected 
patients with early-stage breast cancer. 
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Purpose/Objective: To assess the toxicity of combined 
therapy between external beam radiation therapy (EBRT) 
plus high dose rate brachytherapy (HDRB) as a boost in 
patients with intermediate or high risk prostate cancer. 
Materials and Methods: From 2010 to August 2014, a total of 
221 patients diagnosed as intermediate or high-risk prostate 
cancer were treated with EBRT plus HDRB. Median age was 72 
years (range 52-85). Most patients (68%) were classified as 
high-risk (stage T2c-T3b or PSA >20ng/dl or GS>7), and 70 
patients (32%) were considered intermediate risk. The stage 
of tumor was determined in every case by magnetic 
resonance imaging (MRI). Every patient received first HDRB as 
boost and 4 gold fiducials were implanted. Finally, all 
patients received EBRT by intensity modulated radiotherapy 
technique with imaging guided by CBCT. The patients 
received HDRB as a single 15 Gy implant, followed by EBRT to 
46 Gy in 23 fractions. Thirty seven percent of the high-risk 
patients presented seminal vesicles invasion receiving a 
single 9.5 Gy implant, followed by ERBT to 60 Gy in 30 
fractions. A total of 117 patients (52%) received a dose of 46 
Gy to the true pelvis. In all brachytherapy plans, the 
constraints indicated in the GEC/ESTRO recommendations 
have been respected (Rectum D2cc £75Gy EQD2; Urethra 
D10£ 120Gy EQD2). Most patients (120; 54%) were prescribed 
complete androgen deprivation therapy (ADT), 66 (29%) 
received incomplete ADT and 28 (13%) did not receive ADT. 
GI and GU toxicity was evaluated utilizing the RTOG criteria. 
Median follow-up was 26 months. 
Results: No treatment failure has been observed to the last 
follow-up. The incidences of any acute ≥ Grade 2 GI or GU 
toxicities were 0% and 9% respectively. Dysuria and urgency 
was prevalent symptoms in acute GU toxicity. Late 
genitourinary toxicity included 2 patients (0.9%) with urine 
obstruction requiring intermittent/permanent catheter. One 
case of grade 2 gastrointestinal late toxicity presented 
actinic rectitis event. 
Conclusions: The use of a single 15Gy fraction HDRB as pre-
treatment EBRT boost provides early-term and good 
outcomes in treatment-related toxicity. These data can help 
physicians to assess this scheme of radiotherapy as an 
acceptable option in the prostate carcinoma treatment. 
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Purpose/Objective: APBI is currently considered a viable 
treatment option in early-stage breast cancer patients. 
Mostly due to the rising need to treat patients outside clinical 
trials, in 2009 two consensus statements (CS) were created 
by ASTRO (American Society for Radiation Oncology) and 
GEC-ESTRO (Groupe Européen de Curiethérapie-European 
Society for Radiotherapy and Oncology). More recently, 
guidelines from ABS (American Brachytherapy Society) were 
also published. This helps the train of thought Radiation 
Oncologists have to undergo concerning the decision for the 
most appropriate adjuvant radiation treatment modality in 
early-stage breast cancer patients. Nevertheless, during that 
process, doubts may emerge due to the lack of parallelism 
among the three guidelines that can lead to different risk 
group stratification/treatment indications for the same 
patient. Our study aimed at comparing the rate of suitable 
and unsuitable patients for APBI according to the three 
guidelines. As a secondary objective survival and relapse 
rates were also addressed. 
Materials and Methods: 81 patients submitted to APBI, in a 
single-institution, were retrospectively analyzed (treated 
from 2003 to 2013) and then categorized according to 
indication for treatment as 'suitable', 'cautionary' and 
'unsuitable' (ASTRO), as 'low risk', 'intermediate risk' and 'high 
risk' (GEC-ESTRO), and as 'acceptable' and 'not acceptable' 
(ABS). Data regarding tumour, treatment technique and 
patient-related features was collected, as well as recurrence 
and survival rates. 
Results: Median follow-up time was 35,1 months, 46 patients 
underwent HDR and 35 a PDR technique either with metal 
needles or flexible plastic catheters using a template-based 
system. 75 were suitable for guideline stratification (2 
patients lost to follow-up and 6 without complete 
information about risk factors). According to the ASTRO CS, 
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47 patients were considered 'suitable', 23 'cautionary' and 5 
'unsuitable'. According to GEC-ESTRO, 60 were 'low risk', 7 
'intermediate risk' and 8 'high risk'. 69 patients were defined 
as 'acceptable' and 6 as 'not acceptable' following ABS 
recommendations. 46 of ABS 'acceptable' patients were also 
either 'suitable' or 'low risk' according to ASTRO and GEC-
ESTRO, meaning an accordance rate between guidelines on 
who to definitely treat with APBI of 67%. 6% (n=4) of patients 
with clear indication not to treat by ASTRO and/or GEC-
ESTRO fitted the 'acceptable' group criteria by ABS. No loco-
regional relapses were documented, 1 patient developed 
distant metastasis. 
Conclusions: This study shows a lack of agreement between 
the current guidelines and supports the existing evidence 
that APBI with multicatheter brachytherapy is an effective 
adjuvant treatment modality. 
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Purpose/Objective: To evaluate the role of 3T 
multiparametric MRI (3TmMRI) without endo-rectal coil (ERC) 
in the detection of radiographic local recurrences (rLR) in a 
contemporary cohort of patients with prostate cancer treated 
at our hospital and who presented a biochemical recurrence 
after PR with low PSA levels and to identify clinical 
parameters associated with the findings of the 3TmMRI.  
Materials and Methods: Between 2009 and 2013, 57 patients 
with biochemical recurrence after RP of a PC and considered 
for salvage radiation therapy (SRT) were included. 3TmMRI 
with T2-weighted imaging (T2WI), diffusion weighted imaging 
(DWI) and dynamic contrast-enhanced images (DCE) without 
ERC was carried out in all the patients prior to treatment. 
Given that there are no validated criteria, a points system 
was established to define the findings of the 3TmMRI, 0 being 
(normal; no abnormality was observed in the MRI sequences: 
T2WI, DWI or DCE), 1 being (doubtful; an abnormality was 
detected in one of the MRI sequences, with no correlation in 
the rest of the sequences) and 2 being (abnormal; 
abnormality detected in all or in two of the sequences). The 
local relapse was defined as 2. To analyze the relationship 
between rLR in 3TmMRI and the clinical variables, a logistic 
regression analysis was carried out. 
Results: In 14/57 patients (24.56%) a rLR through 3TmMRI 
was detected. Median pre-SRT PSA was 0.40 ng/ml 
(interquartile range, 0.30-2.05 ng/ml). The location of the 
recurrence was perianastomotic in 8/14 patients (57.14%) 
and retrovesical in 6/14 patients (42.86%). The median size 
of the local recurrence was 15.2 mm (range, 8.0-46.0 mm). 
The median apparent diffusion coefficient (ADC) value on 
DWI was 0.90 mm2/s (range, 0.35-1.58 mm2/s) and 6/14 
patients (42.85%) presented type 3 pathological captation 
curves and 3/14 patients (21.42%) presented type 2 
enhancement curves in the DCE images. Normal prostate 
tissue remains were identified in 9/57 patients (15.78%). 
Pelvic nodal recurrence was evidenced in 4/57 patients 
(7.01%) and pelvic bone metastasis were found in 4/57 
patients (7.01%). 12.90% (4/31) rLR was observed in patients 
with PSA ≤0.5 ng/ml, vs 38.46% (10/26) for PSA>0.5 ng/ml. 
The incidence of rLR according to PSA doubling time (PSADT) 
was 15.% (6/40) for PSADT≤14 months, vs 54.54% (6/11) for 
PSADT>14 months. The probability of rLR was significantly 
higher in patients with PSA levels >0.5 ng/ml (adjusted odds 
ratio (OR): 6.25; 95% confidence interval (CI): 1.27-
30.79;p=0.02), or PSA doubling time (PSADT)>14 months 
(adjusted OR: 7.12; 95% CI:1.40-36.25; p=0.01). 
Conclusions: This is the first study to find a significant 
relationship between the PSADT and the rLR through MRI. 
Patients that benefit most from conducting a 3TmMRI were 
those with PSADT>14 months or with pre-SRT PSA >0.5 ng/ml. 
Its routine use could have significant clinical implications in 
SRT. 
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Purpose/Objective: Recent EORTC studies report an increase 
in survival in breast cancer patients treated with RT when 
the internal mammary node (IMN) is included. The 
aforementioned studies were based on conventional 3D 
irradiation with photons in breast and supraclavicular and 
axillary nodes and a direct electron field in the IMN. To our 
knowledge, the safety of including IMN in IMRT has not been 
studied to date. The objective of the study was to 
retrospectively evaluate the dosimetric impact on the usual 
organs at risk (OAR) in the irradiation of the left breast/chest 
wall (heart, lungs, and contralateral breast) treated with 
IMRT. 
Materials and Methods: We selected all breast patients (n = 
30) treated with IMRT (left breast, left chest wall, 
with/without nodes and with/without boost) in 2014. CT 
planning was performed in all patients with a Philips Big Bore 
CT. We defined the volumes to irradiate and the OAR. We 
performed a new IMRT planning to compare with the previous 
technique. We used our standard distribution of fields in each 
case. Treatment planning and volume definition were defined 
using the Eclipse V8.9 planning system from Varian. After 
optimizing dosimetry to obtain the best coverage and 
homogeneous distribution of PTVs, we compared the dose 
received in OAR for each of the 2 plans, considering the 
constraints of our service (mainly based in QUANTEC), which 
are: 
-Heart: V30<30%; V25<15; Dmean<10Gy 
-Lung: V5<60%; V20<30% 
-Ipsilateral Lung: V20<30% 
-Contralateral Lung: V5<40% 
-Contralateral Breast: V5<2% (This is an orientation constraint 
because heart and lung area priority constraint). 
We recorded the values of these indexes for IMRT with and 
without IMN. 
Results:  
Table 1 shows the mean values recorded for IMRT with and 
without IMN, and the differences between the two plans. We 
found a slight increase in dose in OAR when IMN was 
included, but this increase did not exceed the limits 
established in our service. 
 
 
 
 
Conclusions: IMN irradiation of the left breast can be safely 
performed with the new treatment techniques (IMRT) 
because it does not significantly increase the dose received 
by the OAR. 
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